Iterum Therapeutics
Dublin
About Iterum Therapeutics
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $200.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:ITRM
- Website: iterumtx.com
- Phone: +353 1 903 8920
Industries & Categories
Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/iterum-therapeutics-140869 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.